Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Native gamma delta (γδ) T-cell receptor ligands are a heterogeneous group of molecules that trigger the activation of γδ T cells, a distinct lineage of T lymphocytes that function at the interface of innate and adaptive immunity (Vantourout & Hayday, Nature Reviews Immunology, 2013). Unlike conventional αβ T cells that require MHC-restricted peptide presentation, γδ T cells recognize these native ligands directly or through specialized presenting molecules like butyrophilins (e.g., BTN3A1 and BTN2A1) in an MHC-independent manner (Rigau et al., Science, 2020; Karunakaran et al., Immunity, 2020). Common ligands include metabolic intermediates known as phosphoantigens, such as isopentenyl pyrophosphate (IPP), stress-induced MHC-like molecules like MICA and MICB, and various lipids or proteins (Morita et al., Immunological Reviews, 2007; Groh et al., Science, 1998). These ligands are frequently overexpressed or accumulated in tumor cells and pathogen-infected cells, serving as critical signals for immune recognition. Therapeutic targeting of these ligands, such as through the use of aminobisphosphonates to increase endogenous phosphoantigen levels or monoclonal antibodies to modulate butyrophilin activity, aims to harness the potent anti-tumor and anti-microbial properties of γδ T cells for clinical benefit (Kunzmann et al., Blood, 2000).
Activation of γδ T cells through the recognition of specific native ligands or the stabilization of ligand-receptor complexes (e.g., BTN3A1/BTN2A1), leading to the release of cytotoxic molecules like perforin and granzymes, and pro-inflammatory cytokines such as IFN-gamma and TNF-alpha (Vantourout & Hayday, Nature Reviews Immunology, 2013; Rigau et al., Science, 2020).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Native gamma delta T-cell receptor ligand (Native γδ TCR ligand).